相关实验视频

Updated: Jun 10, 2025

Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample

Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample

Published on: November 21, 2023

SCLC 的瘤免疫微环境与其分子亚型无关

Yoan Velut¹, Basilia Arqué¹, Marie Wislez²

¹Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Institut du cancer Paris CARPEM, Team Inflammation, Complement and Cancer, Paris, France.

European journal of cancer (Oxford, England : 1990)

|October 16, 2024

概括

免疫热小细胞肺癌 (SCLC) 显示出更好的生存率,PD1和PD-L1在免疫细胞上的表达可能作为预后标志物. 对瘤免疫微环境 (TME) 的进一步研究对于SCLC治疗策略至关重要.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
病理学病理学病理学

背景情况:

小细胞肺癌 (SCLC) 是一种具有不良预后的侵袭性癌症.
在SCLC中瘤免疫微环境 (TME) 尚不清楚.
缺乏用于预测SCLC治疗疗效的生物标志物.

研究的目的:

研究SCLC瘤免疫微环境 (TME) 的特征.
确定SCLC中潜在的预后和预测生物标志物.
将SCLC的TME与非小细胞肺癌 (NSCLC) 的TME进行比较.

主要方法:

对48名SCLC患者样本 (2009-2018) 的回顾性分析.
使用定量的7倍体免疫光对T细胞和B细胞进行TME的评估.
与10个NSCLC样本进行比较.
通过ASCL1,NEUROD1和YAP1表达的分子亚型 (免疫组织化学).

主要成果:

免疫热性SCLC,由高免疫细胞密度定义,与较长的整体存活期 (OS) 和早期阶段检测相关.
与NSCLC相比,SCLC显示CD20+细胞密度较低,PD1+细胞密度较高.
在单变量分析中,早期阶段,低NEUROD1表达,高PD1+细胞密度和高PD-L1免疫细胞表达与更高的OS有关.
阶段和PD1+细胞密度是独立的预后标志物.

结论:

这种SCLC TME是异质的.
免疫热瘤与更好的生存系统有关,但不是分子亚型.
免疫细胞上的PD1和PD-L1表达可能作为SCLC的预后标志物.

关键词:

分子子类型的分子.尼乌罗德1是什么意思在PD-L1中.小细胞肺癌是一种小细胞肺癌.瘤的免疫微环境

更多相关视频

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.